Effectiveness of a multidisciplinary heart failure disease management programme on 1-year mortality

Abstract

Supplemental Digital Content is available in the text

Impact of the interruption of a large heart failure regional disease management programme on hospital admission rates: a population‐based study

“…Recruiting centres included all main public and private hospitals and cardiology practices in Lorraine (2.3 million inhabitants). Consistent with pre‐existing evidence, the ICALOR programme was proven to decrease both HF hospitalizations and all‐cause mortality, stabilizing HF hospitalization rate progression in Lorraine, whereas those observed overall in France progressed by approximately 3.5% annually. These results were in line with the results of previous randomized trials, and confirmed the substantial benefit of HF‐DMP on both outcomes of interest in an unselected population of chronic HF patients using observational designs.…”

Adherence to ESC guideline‐recommended medications over a 36‐month follow‐up period after hospitalization for heart failure: Results from the EPICAL2 cohort study

“…The EPICAL2 study was an observational, prospective, multicenter, and population‐based cohort study, previously described in detail elsewhere . Briefly, the cohort involved 21 volunteer hospitals all over the Lorraine region of northeast France (population 2 350 000 according to the 2012 census), which included patients hospitalized for acute HF or acute HF developing during hospitalization from October 2011 to October 2012.…”

Effects of Statins to Reduce All-Cause Mortality in Heart Failure Patients: Findings from the EPICAL2 Cohort Study

“…The methods of recruitment and patient characteristics have been already published elsewhere [7,8]. In brief, this cohort (EPICAL2, NCT02880358) included 2254 patients who were hospitalized in the Lorraine region of northeast France (2,350,000 inhabitants, according to the 2012 census) for acute HF between October 2011 and October 2012 and followed for 1 year after hospital discharge.…”

“…The type of statin could be any of the following: rosuvastatin, pravastatin, atorvastatin, simvastatin, lovastatin, fluvastatin, cerivastatin and pitavastatin. Besides sociodemographic and clinical data, treatment data were collected by standardized forms at inclusion, during the index hospitalization and at discharge [7,8]. The baseline characteristics of included patients are reported in Table 1.…”

“…We included the prescription of BBs, ACE-i, and Table 1 Characteristics of included HF patients according to treatment with statins ACE-i angiotensin-converting-enzyme inhibitor, ARB angiotensin receptor blocker, BBs beta-blockers, BMI body mass index, BNP brain natriuretic peptide, COPD chronic obstructive pulmonary disease, HF heart failure, LVEF left ventricular ejection fraction, NT-proBNP N-terminal prohormone of brain natriuretic peptide, NYHA New York Heart Association classification, SD standard deviation, TIA transient ischemic attack a Values are n (%) unless otherwise stated b Deleted in models for collinearity c BNP > 400 pg/mL or NT-proBNP > 450 pg/mL in patients < 50 years; NT-proBNP > 900 pg/mL in patients 50-75 years; NT-proBNP > 1800 pg/mL in patients > 75 years [7,9] spironolactone among the selected variables because they are known to be associated with a better prognosis [7,9]. We defined the variable "increased BNP or NT-proBNP (pg/mL)" based on the literature [8,10] at the time of the EPICAL2 recruitment phase: BNP > 400 pg/mL or NT-proBNP > 450 pg/mL in patients < 50 years, NT-proBNP > 900 pg/mL in patients 50-75 years, and NT-proBNP > 1800 pg/mL in patients > 75 years. For statistical analysis, we dichotomized some variables: hemoglobin level (< 10 g/dL), hospital stay duration (≥ 9 days), and hypertensive cardiomyopathy (yes or no).…”